169 related articles for article (PubMed ID: 17967058)
41. Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism.
Marin M; Golem S; Rose KM; Kozak SL; Kabat D
J Virol; 2008 Jan; 82(2):987-98. PubMed ID: 17977970
[TBL] [Abstract][Full Text] [Related]
42. Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif.
Shirakawa K; Takaori-Kondo A; Yokoyama M; Izumi T; Matsui M; Io K; Sato T; Sato H; Uchiyama T
Nat Struct Mol Biol; 2008 Nov; 15(11):1184-91. PubMed ID: 18836454
[TBL] [Abstract][Full Text] [Related]
43. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
Mehle A; Strack B; Ancuta P; Zhang C; McPike M; Gabuzda D
J Biol Chem; 2004 Feb; 279(9):7792-8. PubMed ID: 14672928
[TBL] [Abstract][Full Text] [Related]
44. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
Stopak K; de Noronha C; Yonemoto W; Greene WC
Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
[TBL] [Abstract][Full Text] [Related]
45. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
46. gag, vif, and nef genes contribute to the homologous viral interference induced by a nonproducer human immunodeficiency virus type 1 (HIV-1) variant: identification of novel HIV-1-inhibiting viral protein mutants.
D'Aloja P; Olivetta E; Bona R; Nappi F; Pedacchia D; Pugliese K; Ferrari G; Verani P; Federico M
J Virol; 1998 May; 72(5):4308-19. PubMed ID: 9557721
[TBL] [Abstract][Full Text] [Related]
47. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study.
Bernacchi S; Henriet S; Dumas P; Paillart JC; Marquet R
J Biol Chem; 2007 Sep; 282(36):26361-8. PubMed ID: 17609216
[TBL] [Abstract][Full Text] [Related]
48. HIV-1 Adapts To Replicate in Cells Expressing Common Marmoset APOBEC3G and BST2.
Fernández-Oliva A; Finzi A; Haim H; Menéndez-Arias L; Sodroski J; Pacheco B
J Virol; 2016 Jan; 90(2):725-40. PubMed ID: 26512082
[TBL] [Abstract][Full Text] [Related]
49. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules.
Kozak SL; Marin M; Rose KM; Bystrom C; Kabat D
J Biol Chem; 2006 Sep; 281(39):29105-19. PubMed ID: 16887808
[TBL] [Abstract][Full Text] [Related]
50. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
[TBL] [Abstract][Full Text] [Related]
51. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3).
Pillai SK; Wong JK; Barbour JD
Retrovirology; 2008 Mar; 5():26. PubMed ID: 18339206
[TBL] [Abstract][Full Text] [Related]
52. Regulation of HIV-1 infection in cells derived from purified CD34+ cells through manipulation of APOBEC3G expression.
Heinzelmann A; Stein S; Köhl U; Dietrich U; von Briesen H
Curr HIV Res; 2010 Oct; 8(7):554-63. PubMed ID: 20642434
[TBL] [Abstract][Full Text] [Related]
53. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
54. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T
J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111
[TBL] [Abstract][Full Text] [Related]
55. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
Liu B; Yu X; Luo K; Yu Y; Yu XF
J Virol; 2004 Feb; 78(4):2072-81. PubMed ID: 14747572
[TBL] [Abstract][Full Text] [Related]
56. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
57. Divergence in Dimerization and Activity of Primate APOBEC3C.
Gaba A; Hix MA; Suhail S; Flath B; Boysan B; Williams DR; Pelletier T; Emerman M; Morcos F; Cisneros GA; Chelico L
J Mol Biol; 2021 Dec; 433(24):167306. PubMed ID: 34666043
[TBL] [Abstract][Full Text] [Related]
58. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.
Donahue JP; Vetter ML; Mukhtar NA; D'Aquila RT
Virology; 2008 Jul; 377(1):49-53. PubMed ID: 18499212
[TBL] [Abstract][Full Text] [Related]
59. Comparative analysis of the gene-inactivating potential of retroviral restriction factors APOBEC3F and APOBEC3G.
Bélanger K; Langlois MA
J Gen Virol; 2015 Sep; 96(9):2878-2887. PubMed ID: 26048885
[TBL] [Abstract][Full Text] [Related]
60. Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression.
Amoêdo ND; Afonso AO; Cunha SM; Oliveira RH; Machado ES; Soares MA
PLoS One; 2011; 6(8):e24118. PubMed ID: 21897871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
